Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

SIMPLE SUMMARY: Patients with relapsing/refractory B-cell lymphoma who respond to a platinum salt-based salvage regimen can be cured after therapy intensification followed by autologous stem cell transplantation. The Bruton tyrosine kinase inhibitor ibrutinib, given alone or in association with othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnet, Christophe, Dupuis, Jehan, Tilly, Hervé, Lamy, Thierry, Fruchart, Christophe, le Gouill, Steven, Thieblemont, Catherine, Morschhauser, Franck, Casasnovas, Olivier, Bouabdallah, Krimo, Ghesquieres, Hervé, Van Den Neste, Eric, André, Marc, Cartron, Guillaume, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997053/
https://www.ncbi.nlm.nih.gov/pubmed/35406532
http://dx.doi.org/10.3390/cancers14071761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997053/
https://www.ncbi.nlm.nih.gov/pubmed/35406532
http://dx.doi.org/10.3390/cancers14071761

Ejemplares similares